Backed by baby-food mogul Paul Manning, Durham drug developer plans IPO

Backed by baby-food mogul Paul Manning, Durham drug developer plans IPO

North Carolina’s life-science industry gets more intriguing by the day, it seems. The state’s newest public company is likely to be Dova Pharmaceuticals, a Durham-based drug developer that filed June 2 for a $75 million initial public offering. Its drugs are intended to focus on low blood platelet count disorders.

Director Paul B. Manning, 61, controls 85% of the company’s stock through his PBM Capital private-equity group. A resident of Charlottesville, Va., he founded his fund after selling his infant-formula and baby-food company, PBM, to Perrigo Corp. for $800 million in 2010.

Another investor, Perceptive Life Sciences Master Fund, invested $10 million in Dova late last year as part of a $29 million series A funding.

Dova has posted $27 million in net losses since its March 2016 inception, mostly from R&D expenses. It has not generated revenue.

CEO Alex Sapir, 50, is a former exec at United Therapeutics, the Maryland-based pharma company with a big Triangle presence. Manning’s PBM Capital has had success in other drug-development investments.

But biotech investing isn’t for the faint of heart. Dova Chief Medical Officer Lee Allen previously worked at Durham-based Argos Therapeutics, which went public in 2014 for about $10 a share but now trades at less than 50 cents.

J.P. Morgan, Jefferies, and Leerink Partners are Dova’s main deal underwriters.

Click to read...  Durham Bulls to implement new safety netting above dugouts
Privacy Policy | Terms of Service | Curation Policy | DMCA Policy